Scorpion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.scorpiontx.com
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06043817
- Locations
- 🇺🇸
Thomas Jefferson University Research Facility, Philadelphia, Pennsylvania, United States
🇰🇷Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Spain
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05768139
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇮🇹Fondazione Policlinico Universitario A Gemelli-Rome, Roma, Lazio, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, Lombardia, Italy
© Copyright 2024. All Rights Reserved by MedPath